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Abstract
PFOS is a chemical of nearly ubiquitous exposure in humans. Recent studies have associated 
PFOS exposure to adipose tissue-related effects. The present study was to determine whether 
PFOS alters the process of adipogenesis and regulates insulin-stimulated glucose uptake in mouse 
and human preadipocytes. In murine-derived 3T3-L1 preadipocytes, PFOS enhanced hormone-
induced differentiation to adipocytes and adipogenic gene expression, increased insulin-stimulated 
glucose uptake at concentrations ranging from 10 to 100 µM, and enhanced Glucose transporter 
type 4 and Insulin receptor substrate-1 expression. Nuclear factor (erythroid-derived 2)-like 2 
(Nrf2), NAD(P)H dehydrogenase, quinone 1 and Glutamate-cysteine ligase, catalytic subunit were 
significantly induced in 3T3-L1 cells treated with PFOS, along with a robust induction of 
Antioxidant Response Element (ARE) reporter in mouse embryonic fibroblasts isolated from 
ARE-hPAP transgenic mice by PFOS treatment. Chromatin immunoprecipitation assays further 
illustrated that PFOS increased Nrf2 binding to ARE sites in mouse Nqo1 promoter, suggesting 
that PFOS activated Nrf2 signaling in murine-derived preadipocytes. Additionally, PFOS 
administration in mice (100 µg/kg/day) induced adipogenic gene expression and activated Nrf2 
signaling in epididymal white adipose tissue. Moreover, the treatment on human visceral 
preadipocytes illustrated that PFOS (5 and 50 µM) promoted adipogenesis and increased cellular 
lipid accumulation. It was observed that PFOS increased Nrf2 binding to ARE sites in association 
with Nrf2 signaling activation, induction of Peroxisome proliferator-activated receptor γ and 
CCAAT/enhancer-binding protein α expression, and increased adipogenesis. This study points to 
a potential role PFOS in dysregulation of adipose tissue expandability, and warrants further 
investigations on the adverse effects of persistent pollutants on human health.
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Introduction
Perfluorooctane sulfonate (C8HF17O3S, PFOS) and Perfluorooctanoic acid (C8HF15O2, 
PFOA) are organic fluoroalkyl chemicals widely used in industrial and consumer 
applications as powerful surfactants and building material components, as they are stable at 
high temperature and nonflammable (Olsen et al., 2005). These two chemicals have been 
detected worldwide in the environment, including drinking water (Skutlarek et al., 2006), 
atmosphere air (Shoeib et al., 2005), soil, sediments (Boulanger et al., 2005), and even the 
wildlife in the Antarctic Pole (Giesy and Kannan, 2001). Average human serum PFOS and 
PFOA content has decreased between 2000 and 2005 due to the phase out of 
Perfluorooctanesulfonyl-fluoride (POSF, C8F17SO2F)-based materials by the primary 
global manufacturer, 3M Company, in May 2000 (Olsen et al., 2007b), but the related health 
effects still remain a concern. Although have been banned in United States and Europe, 
PFOS and PFOS-related chemicals are still currently produced in China.
Importantly, PFOS and PFOA are readily absorbed and poorly eliminated from humans. 
Increased renal absorption via transport mechanisms is suspected to be the mechanism that 
contributes to the relatively long serum half-lives observed in humans (Olsen et al., 2007a), 
which has been estimated to 5.4 (PFOS) and 3.8 (PFOA) years. Because of its persistence in 
the body and presence in populations across the world, it is important to assess potential 
health effects. Liver is the major organ affected by exposure of PFOS in animal models. It is 
known that PFOS will be deposited in liver, which associated with increased liver weight in 
rats, mice, and monkeys (Chang et al., 2012; Wan et al., 2012). Exposure of PFOS has been 
shown to induce further undesirable effects, such as increased hepatic lipid accumulation 
along with significant induction of Cluster of differentiation 36 (FAT/CD36) and 
Lipoprotein lipase (Lpl) expression, which resulted in disturbance of lipid metabolism and 
excessive fatty liver (Wan et al., 2012). In addition, dietary administration of PFOS in mice 
(0.005%, w/w) for 10 days reduced serum cholesterol and triglycerides levels, and induced a 
moderate hepatomegaly (Qazi et al., 2010). More recent publications reported that exposure 
of PFOS altered expression of genes mainly involved in lipid modulation, energy 
metabolism, reproduction, hormone regulation, suggesting a role for PFOS in regulating 
lipid metabolism and development (Hu et al., 2005; Hagenaars et al., 2008). The observed 
hepatomegaly that results from PFOS administration is due to Peroxisome proliferator-
activated receptor (Ppar) activation (Takacs and Abbott, 2007; Bjork and Wallace, 2009). 
Rosen et al. also reported that PFOS may modulate various gene expression related to lipid 
metabolism, inflammation, and xenobiotic metabolism via Pparα-independent mechanisms, 
such as the modest activation of Constitutive Androstane Receptor (CAR) and Pparγ 
signaling pathway (Rosen et al., 2010). And PFOA was reported to induce various 
xenobiotic metabolism genes, which were under the control of CAR and transcription factor 
of Nuclear factor erythoid 2-related factor 2 (Nrf2) (Rosen et al., 2008). However, PFOS 
effects on adipogenesis and white adipose tissue (WAT) expansion were still unknown.
Xu et al. Page 2
Toxicol Appl Pharmacol. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Adipogenesis is a process involving sequential coordinated gene induction (Rosen and 
Spiegelman, 2000). CCAAT/enhancer-binding protein (Cebp) δ and Cebpβ induce the 
expression of Pparγ, which activates Cebpα expression, and these two transcriptional factors 
of Pparγ and Cebpα can work in concert to maintain the differentiated status. Subsequently, 
Pparγ and Cebpα activation induce the subsequent steps of adipogenesis and lipogenesis. 
Gain-of-function experiments that forced Pparγ and/or in combination with potential 
agonists demonstrated that non-adipogenic, fibroblast cells can be transdifferentiated to 
adipocytes (Wu et al., 1995). Emerging data points to new regulators of Ppar signaling 
pathway, such as transcription factor of Nrf2, regulated lipid metabolism and the process of 
adipogenesis (Shin et al., 2007; Pi et al., 2010). Classically, Nrf2 binds to Antioxidant-
Responsive Elements (ARE), induces expression of a battery of detoxification and 
antioxidant genes to counter cellular electrophilic and oxidative stress (Kensler et al., 2007; 
Klaassen and Reisman, 2010). Pi et al. reported that an ARE element exists in mouse Pparγ 
promoter, and loss of Nrf2 reduced Pparγ expression and prevented the process of 
adipogenesis in 3T3-L1 preadipocytes (Pi et al., 2010). This work provided a link between 
Nrf2 and adipogenesis. Other studies have demonstrated that too much Nrf2 activation can 
also perturb adipogeneis. An early study by Kensler et al. described Nrf2 prevented 
adipogenesis via modulating Aryl hydrocarbon receptor Signaling (Shin et al., 2007). Our 
previous results demonstrated that enhanced Nrf2 activity via Kelch-like ECH-associated 
protein 1 - knockdown (Keap1-KD) inhibited WAT expansion and the adipocyte 
differentiation, suggesting the Nrf2-independent mechanism involved in Keap1-KD system 
(Xu et al., 2012). The relationship of PFOS and Nrf2 has been reported in zebrafish in 2010. 
In the publication, the authors reported that PFOS increased cellular ROS content. 
Activation of Nrf2 signaling by sulforaphane reduced ROS content, further reduced MAPK 
activation of JNK and p38 signaling, suggesting that Nrf2 signaling regulated PFOS-induced 
oxidative stress (Shi and Zhou, 2010).
To evaluate the effect of PFOS on adipogenesis, and further explore its effects on regulating 
WAT expansion and the development of obesity, 3T3-L1 preadipocytes were induced to 
differentiation to adipocytes with the presence of PFOS with the dose of environmental 
exposure-relevant concentrations. The cellular lipid content and adipogenic gene expression 
were evaluated. Additionally, glucose uptake was determined in the mature adipocytes with 
PFOS administration. Lastly, PFOS-induced adipogenic effects were also evaluated in a 
whole animal model with daily PFOS administration and in human visceral preadipocytes. 
The current study demonstrates that PFOS induces Nrf2 activation in association with 
promoting Pparγ and Cebpα signaling, and induction of adipogenesis that increases lipid 
accumulation in 3T3-L1 preadipocytes. Moreover, pro-adipogenic effects were observed in 
human visceral preadipocytes exposed to PFOS.
Material and Methods
Chemicals
Heptadecaperfluorooctanesulfonic acid potassium salt (#77282, PFOS), insulin (#I6634), 
dexamethasone (#D4902, DEX) isobutylmethylxanthine (#I5879, IBMX), and Oil Red O 
(#O0625) were got from Sigma-Aldrich (St. Louis, MO). Ethanol, methanol, isopropanol, 
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MTT solution and other chemicals without specific illustration were got from Thermo Fisher 
Scientific Inc. (Waltham, MA)
Animals and PFOS administration
10-week-old male C57BL/6 mice weighing approximately 30 grams were purchased from 
Charles River Laboratories (Wilmington, MA). The mice were housed under a controlled 
temperature (22–25 °C) with relative humidity (30–70%), lighting (12 hrs, light-dark cycles) 
environment and acclimated for 5 weeks on the standard rodent chow to allow for additional 
weight gain. At 15 weeks of age, the mice were then fed a purified rodent chow (AIN-93G 
Growth Purified Diet, TestDiet, St. Louis, MO). At 21 weeks of age, mice (n=8) were 
administered water as vehicle via oral gavage (5 mL/kg) or PFOS (100 µg/kg, 5 mL/kg) for 
36 days. Body weight and food intake were monitored daily and recorded. Epididymal WAT 
was collected, snap frozen with liquid nitrogen, and stored at −70 °C until analysis. All 
procedures were conducted in accordance with the NIH Guidelines for the Care and Use of 
Laboratory Animals and were approved by the University of Rhode Island Animal Care and 
Use Committee.
Acute cytotoxicity assay
A minimum of 5 replicates of 7,500 3T3-L1 preadipocytes per well were plated in 96-well 
plates and allowed to adhere to the plate for approximately 12 hrs, at which time the media 
was removed and replaced with fresh media containing varying concentrations of PFOS in 
DMSO (1 nM, 5 nM, 10 nM, 100 nM, 500 nM, 1 µM, 5 µM, 10 µM, 50 µM, 100 µM). Cells 
were subsequently incubated for an additional 48 hrs. Then 20 µL MTT solution (5 mg/mL 
in PBS) was added and the plate was incubated for another 3 hrs. The supernatant was 
removed carefully and 150 µL MTT solvent (4 mM HCl, 0.1% NP-40 in isopropanol) was 
added to each well. The plate was covered with foil and agitated on an orbital shaker for 15 
mins. The cell viability was determined by measuring the absorbance at 590 nm with 620 
nm as reference filter. Relative cell viability (%) was displayed using vehicle (0.1% 
DMSO)-treated samples as a standard.
Cell culture and 3T3-L1 pre-adipocyte differentiation
Mouse 3T3-L1 (ATCC® CL-173™) preadipocytes were obtained from ATCC (American 
Type Culture Collection, Manassas, VA, USA) and maintained in high-glucose DMEM 
medium supplemented with 10% fetal bovine serum (FBS). 3T3-L1 preadipocyte 
differentiation was induced according to the protocol described previously (Shin et al., 
2007; Xu et al., 2012). Briefly, 2 days post 100% confluence, 3T3-L1 preadipocytes were 
stimulated to differentiation to adipocytes in a standard adipogenic differentiation medium 
(DMEM containing 10% FBS, 10 µg/mL insulin, 1 µM DEX, 0.5 mM IBMX), which was 
considered Day0. Cells were cultured in the latter media for Days 0–3 and then cultured in 
DMEM containing 10% FBS and 10 µg/mL insulin for the remaining days. Media was 
refreshed every 2 days. Cell treatment and corresponding assay were described as Figure 
1A.
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Human visceral preadipocytes culture and induction to adipocytes
Poietics™ Human visceral preadipocytes (Donor #: 24711; Lot #:0000313366; Cat #: 
PT-5005) were obtained from Lonza (Lonza Walkersville, Inc., Walkersville, MD) and 
maintained in PBM-2 media according to the manufacturer’s instructions. The preadipocytes 
were plated at 8,700 cells per well. Cells were induced to differentiation to adipocytes by 
switching with the differentiated media of PBM-2 supplementing with dexamethasone, 
isobutylmethylxanthine and insulinSingleQuots™ 24 hrs post 100% confluence and keep in 
the same media for the next 11 days. Cells were treated with DMSO (0.1%) or PFOS (5 or 
100 µM) in quadruplicates. Oil red O was used to image the lipid droplets. The cellular lipid 
was purified via isopropanol extraction and the lipid content was quantified 
spectrophotometrically at what 520 nm. Cell treatment and corresponding assay were 
described as Figure 1B.
RNA isolation and quantitative real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen, CA) according to the 
manufacturer’s instructions. One microgram of total RNA was converted to cDNA and 
mRNA levels were quantified by quantitative real-time PCR using a Roche LightCycler 480 
System (Roche Applied Science, Mannheim, Germany). SYBR green chemistry was used 
and relative target gene expression was normalized to 18S rRNA. The primers used are 
listed in Supplementary Table 1.
Oil Red O staining
3T3-L1 preadipocytes or human visceral preadipocytes were induced to differentiation to 
adipocytes. The supernatant was removed and cell layer was washed twice with 2 mL ice-
cold PBS. Cells were fixed with 10% formalin at 4 °C for 30 mins, then stained with Oil 
Red O solution (six parts Oil Red O stock solution [0.5% Oil Red O in 100% isopropanol] 
and four parts H2O) for 60 mins. Cells were counterstained with hematoxylin and mounted 
in glycerin jelly (Carolina Biological Supply Company, Burlington, NC).
Measurement of triglycerides in 3T3-L1 preadipocytes
3T3-L1 preadipocytes plated on 60-mm dishes were induced to adipocytes for 8 days. Lipids 
were extracted according to a previous protocol (Xu et al., 2012). Triglycerides content were 
determined with reagent kits (Pointe Scientific, Inc, MI), and the absorbance was measured 
spectrophotometrically at 520 nm. Relative triglycerides content (%) was displayed using 
differentiation medium containing 0.1% DMSO - treated cells as a standard.
Glucose uptake assay
Glucose uptake in 3T3-L1 mature adipocytes was measured by using 2-[N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glucose (2-NBDG) according to the manufacturer’s 
instructions (Cayman Chemical Company, MI). In brief, 3T3-L1 preadipocytes plated on 
96-well fluorescent plates were induced to adipocytes as described above. At Day11, cells 
were washed with PBS and then treated with serum-free DMEM containing PFOS (0 – 100 
µM) or DMSO (0.1%) for 5 hrs. Then cells were washed with sterilized PBS for 3 times, and 
stimulated with 100 nM insulin for 20 mins in KRPH buffer (20 mM HEPES, 5 mM 
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KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 136 mM NaCl, and 4.7 mM KCl, pH 7.4) with the 
presence of PFOS or DMSO, respectively. Glucose uptake was initiated by the addition of 
100 µg/mL 2-NBDG to each well. The fluorescence activity was monitored at an excitation 
wavelength of 485 nm and an emission wavelength of 535 nm. At least eight replicates for 
each dosage was performed. Relative glucose uptake was displayed using vehicle-treated 
group as a standard.
hPAP induction assay
Mouse embryonic fibroblast (MEF) differentiation to adipocytes was performed as 
described elsewhere (Shin et al., 2007; Xu et al., 2012). MEFs were isolated from 13.5- to 
15.5-d post coital mouse embryos from ARE-hPAP transgenic mice, then cells were 
cultured in DMEM supplemented with 10% FBS in 10 cm culture dishes (Johnson et al., 
2002). MEFs were collected and cultured in 6-well plate, 2 days post of 100% confluence, 
cells were switched to differentiated media with DMEM containing 10% FBS, 10 µg/mL 
insulin, 1 µM DEX, 0.5 mM IBMX (Day0). Three days later, cells were switched to media 
only containing 10% FBS and 10 µg/mL insulin for the remaining days. And four days post 
differentiation, total RNA was extracted and the relative mRNA levels of hPAP were 
measured using quantitative real-time PCR. The detailed design was described as Figure 1C.
Chromatin Immunoprecipitation (ChIP) assay
3T3-L1 cells were induced to adipocytes as described above. Two days post differentiation 
to adipocytes, cells were harvested and the Chip assay was performed according to the 
manufacturer’s instructions (Active Motif, Carlsbad, CA). Equal amount of sheared 
chromatin DNA (15 µg) was incubated with anti-Nrf2 antibody (Cell Signaling, Danvers, 
MA) or IgG as negative control overnight at 4 °C. A portion of sheared chromatin DNA was 
preserved as input (10 µL). Purified DNA was PCR-amplified for 35 cycles (30 s at 94 °C, 
30 s at 59 °C, and 30 s at 72 °C) with the primers that cover putative AREs sequences in 
mouse Nqo-1 promoters (Forward: 5’-GCAGTTTCTAAGAGCAGAACG-3’; Reverse: 5’-
GTAGATTAGTCCTCACTCAGCCG-3’).
Statistical Analysis
Quantitative data were presented as average ± SE. Statistic differences were determined by a 
one-way ANOVA followed by a Duncan’s Multiple Range post hoc test. All statistical tests 
with P<0.05 were considered significant.
Results
PFOS induces adipogenesis in 3T3-L1 preadipocytes
In order to explore the association of PFOS exposure and adipocyte differentiation, we 
determined the effect of PFOS concentrations on 3T3-L1 pre-adipocyte viability. No overt 
toxicity was observed at <50 µM in the current study (Figure 1D). 3T3-L1 preadipocytes 
were differentiated to adipocytes in the presence of differentiated cocktail with or without 
PFOS. Oil Red O staining of mature lipid-containing adipocytes at Day8 was performed to 
evaluate PFOS effects on adipogenesis. Figure 2A illustrates that high concentrations of 
PFOS (1–100 µM) increased lipid accumulation in 3T3-L1 adipocytes compared to vehicle-
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treated group (Figure 2A). However, staining was similar between vehicle- and PFOS-
treated groups treated with concentrations less than 1 µM (1–500 nM), except there was 
lower lipid content at the dosage of 5 nM (Figure, 2B, Figure, S1). Similar to the observed 
staining, higher PFOS concentrations (1–50 µM) increased triglycerides content in 3T3-L1 
adipocytes by more than 20% above control, but this effect was not observed with the 
relatively lower PFOS concentrations (1–100 nM) (Figure 2B). The data suggest that PFOS 
has the potential to potentiate induction of mouse preadipocyte differentiation to mature 
adipocytes and promote lipid accumulation.
PFOS increases adipogenic gene expression in 3T3-L1 preadipocytes
The underlying molecular mechanisms for PFOS function on adipogenesis were evaluated. 
3T3-L1 preadipocytes were induced to adipocytes with PFOS administration for continuous 
3 days, total RNA was extracted and the relative mRNA levels of genes related with 
adipogenesis of Cebpα, Pparγ, Fatty acid-binding protein 4 (Fabp4) and Lpl were 
determined. There is no significant difference for these four genes expression between 
vehicle- and PFOS-treated groups at Day1. After induction to adipocytes for 3 days (Day3), 
Cebpα, Pparγ, Fabp4 and Lpl were significantly induced in both groups; with induction 
being significantly higher in PFOS-treated adipocytes than vehicle-treated group (increased 
by 32.2-, 14.2-, 8.6-, and 19.7-fold, respectively), suggesting PFOS increased adipogenic 
gene expression, which may contribute to the increased adipogenesis (Figure 3A). 
Additionally, the mRNA levels of Nrf2 and two target genes, NAD(P)H dehydrogenase, 
quinone 1 (Nqo1) and Glutamate-cysteine ligase, catalytic subunit (Gclc) were determined. 
At Day1, PFOS-treatment slightly decreased Nqo1 and Gclc mRNA levels compared to 
vehicle-treated group. After 3 days of induction to adipocytes (Day3), PFOS significantly 
increased Nrf2, Nqo1 and Gclc mRNA levels in 3T3-L1 adipocytes than vehicle-treated 
group by more than 15-fold, suggesting that PFOS has the potential to activate Nrf2 
signaling in preadipocytes (Figure 3B).
PFOS promotes insulin-stimulated glucose uptake in 3T3-L1 adipocytes
In order to assess the metabolic consequence of PFOS treatment in 3T3-L1 preadipocytes, 
insulin-stimulated glucose uptake were monitored in vehicle- and PFOS-treated adipocytes. 
After 3T3-L1 preadipocytes were differentiated to adipocytes for 10 days, cells were 
exposed to PFOS for 5 hrs, then 2-NBDG was added, and the fluorescence activity was 
monitored. There was no significant difference between the low dose PFOS treatments (1 
and 5 µM) and vehicle-treated group. However, insulin-stimulated glucose uptake was 
significantly higher in PFOS-treated at the concentration of 10 µM than vehicle-treated 
group (by 26%). And a dose-dependent increase of glucose uptake by PFOS-treatment was 
observed, with the highest induction being at the dosage of 100 µM (61.0% higher than 
vehicle) (Figure 4A). The gene expression related to insulin signaling and glucose 
metabolism was monitored. Low dose PFOS treatment (1 µM) did not affect Pparγ, Sterol 
regulatory element-binding protein 1 (Srebp1c), Glucose transporter type 4 (Glut4), Insulin 
receptor substrate 1 (Irs-1), and Insulin Receptor (Insr) gene expression. However, treatment 
with 10 or 50 µM PFOS increased Pparγ, Srebp1c, Glut4 and Irs-1 expression compared to 
vehicle-treated group (by 1.3-, 1.8-, 1.7-, 1.4-and 1.2-, 1.3-, 1.2-, 1.2-fold, respectively), but 
with similar Insr expression between vehicle- and PFOS-treated groups (Figure 4B). It was 
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hypothesized that in the early induction process, PFOS might induce the antioxidant 
response, then leading to Nrf2 activation that augmented Pparγ induction (Shi and Zhou, 
2010). PFOS (1 µM) did not induce Nrf2 or Nqo1 expression, but expression was induced 
by about 30% in cells treated with 10 and 50 µM PFOS, suggesting the potential role of 
PFOS activating Nrf2 signaling in mature adipocytes (Figure 4C).
Adipogenic gene expression and Nrf2 signaling is increased in white adipose tissue from 
mice administered PFOS
C57BL/6 male mice were administered PFOS for 36 days (100 µg/kg/day) and the transcript 
levels corresponding to adipogenesis and Nrf2 signaling were measured in epididymal 
WAT. PFOS significantly increased the expression of adipogenic genes, including Cebpα, 
Pparγ, Fabp4 and Lpl in WAT (by 66.4%, 93.2%, 73.3%, and 67.6%). Srebp1c and Insr, 
related with insulin signaling, were significantly induced after PFOS administration (by 
67.2% and 59.7%), along with the increasing tread of Glut4 and Irs-1 expression (by 44.1% 
and 25.9%) (Figure 5A). Additionally, PFOS significantly induced Nrf2, Nqo1 and Gclc 
mRNA levels (by 97.2%, 173.0% and 87.3%), suggesting enhanced Nrf2 signaling in WAT 
of mice administrated with PFOS. Expression of Heme oxygenase 1 (Ho-1), Multidrug 
resistance-associated protein (Mrp) 2, Mrp4, UDP-glucuronosyltransferase (Ugt) 1a6, and 
Superoxide dismutase (Sod) 1, which are highly associated with Nrf2 signaling 
(Thimmulappa et al., 2002; Dreger et al., 2009), were increased in the current study (37.6%, 
26.0%, 334%, 65.2%, and 48.1% higher than vehicle-treated group). PFOS decreased 
Cytochrome P450, family 7, subfamily A, polypeptide 1 (Cyp7a1) by 78.5%, which is 
consistent with the previous study (Chang et al., 2009).
PFOS increased lipid accumulation in differentiated human visceral preadipocytes
Human visceral preadipocytes were obtained and differentiated to adipocytes, and cellular 
lipid content was evaluated by Oil red O staining. Eleven days post-differentiation, PFOS (5 
and 50 µM) significantly increased staining in mature adipocytes (Figure 6A). Furthermore, 
the stain was extracted and quantified spectrophotometrically. Figure 6B illustrates that 
PFOS increased staining in adipocytes by 48% at 5 µM and 40% at 50 µM, suggesting PFOS 
may increase adipogenesis in human visceral preadipocytes, contribute to enhance lipid 
accumulation in PFOS-treated group (Figure 6B).
PFOS increases Antioxidant Response Element activity and enhances Nrf2 enrichment at 
the ARE element in mouse Nqo1 promoter
Some recent work indicates that the Nrf2 pathway is inducible in MEFs and adipose tissue 
(Shin et al., 2007; Xu et al., 2012). In order to determine whether PFOS induces Nrf2 
signaling and might increase adipogenesis via the Nrf2 signaling pathway, MEFs from 
ARE-hPAP transgenic mice (Johnson et al., 2002) were isolated and differentiated to 
adipocytes with or without PFOS for 4 days. Next, hPAP mRNA levels were measured by 
quantitative real-time PCR. PFOS treatment (50 µM) doubled hPAP mRNA levels compared 
to vehicle controls (Figure 7), highly suggesting PFOS increased ARE binding activity 
(Figure 7A). Furthermore, to determine whether the increased ARE binding was via the 
increased Nrf2 binding in PFOS treatment, Chip assay was carried out. Figure 7B and 7C 
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illustrate that two days into differentiation, PFOS increased Nrf2 binding to ARE sites in 
mouse Nqo1 promoter (by 31%), suggesting that Nrf2 binding was increased after PFOS 
treatment during the differentiation process (Figure 7B, 7C).
Discussion
PFOS has been manufactured for over 60 years. Epidemiological studies and recent research 
with PFOS primarily focuses on widespread exposure (Giesy and Kannan, 2001; Olsen et 
al., 2005), hepatic effects in humans (Nelson et al., 2010), primates (Chang et al., 2012) and 
rodents (Wan et al., 2012), and metabolic perturbations (Wan et al., 2012). However, PFOS 
effects on adipogenesis or adipocyte health is largely undescribed, yet is of growing concern 
because of the growing population of obese people worldwide. In the current study, we 
demonstrated that PFOS augmented adipocyte differentiation, increased the expression of 
key transcription factors of Pparγ and Cebpα involved in adipogenesis, and increased ARE 
binding activity and activation of Nrf2 signaling, which increase the binding to promoters 
for oxidative stress-related and adipogenic genes, suggesting the potential roles of PFOS 
regulating white adipose tissue expansion and the related obesity.
The activation of Pparγ by PFOS suggested that PFOS has Pparα-independent mechanism, 
which is in agreement with the previous study (Rosen et al., 2010). PFOS increased liver 
weight and caused modest hepatomegaly, which related with the activation of peroxisome 
proliferator, consistent with the effects of Pparα activator WY14,643. Also, PFOS induced 
both mouse and human Pparα activation, but exerted a greater level of induction of mouse 
Pparα than human Pparα at similar concentrations (Takacs and Abbott, 2007). It has been 
reported that PFOS increased Pparγ-luciferance reporter plasmid activity at the 
concentration from 1 to 100 µM, with little toxicity at the concentration of 250 µM (Takacs 
and Abbott, 2007), illustrated that the dosage of 50 µM used in the current study is the 
optimal concentration for PFOS treatment in vitro.
Pparγ activation is the key process for adipocyte differentiation in 3T3-L1 preadipocytes. 
Pparγ is needed for adipose tissue formation in mice, and in a loss-of-function experiment, 
adipocyte differentiation and WAT expansion was impaired, and did not develop glucose 
intolerance and insulin resistance, suggesting the central role for adipogenesis (Jones et al., 
2005). We failed to observe WAT expansion in mice administered with PFOS (100 µg/kg/
day) for 36 days (Figure S2). This lack of effect could be explained by the relatively low 
dose of PFOS has been used in the current study, but is consistent with other reports. Qazi et 
al. have used 0.005% (W/W) dietary treatment of PFOS for 10 days with male mice, 
resulted in significant reductions for serum cholesterol and triglycerides content (Qazi et al., 
2010). And male BALB/c mice fed with high-fat diet (HFD) with the exposure of PFOS at 
the dose of 5 or 20 mg/kg/day for 14 days, exhibited reduced serum lipid and lipoprotein 
content, but significantly increased hepatic lipid accumulation, probably via Pparα-
independent pathway (Wang et al., 2014). Also, compared to liver, PFOS deposits to a much 
lower concentration in WAT (Maestri et al., 2006). So perhaps the low dose of PFOS 
administered might not have a positive induction in adipose tissue expansion in vivo, despite 
this treatment inducing adipogenic gene expression at transcriptional levels. It was estimated 
that the possible range of environmental exposure dosage for human in European countries 
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such as Italy, the Netherlands, Sweden and the UK, was between 45 and 58 µg/kg/day based 
on the mean consumption (Saikat et al., 2013). Dose of 100 µg/kg/day was used in the 
current study, as planning to mimic the effects of environmental levels exposure of PFOS on 
WAT expansion and the possible function on obesity in animal model of mice. The second 
possible reason is that PFOS has a potential function to induce Pparα activation (Shipley et 
al., 2004). Increased Pparα in adipose tissue could induce lipolysis and promote β-oxidation 
(Reddy and Hashimoto, 2001; Goto et al., 2011), which is beneficial to prevent the lipid 
accumulation to adipose tissue and decrease white adipose tissue mass. It was noted that 
contradict results have been reported that PFOS administration reduced WAT mass, the 
ventral fat was significantly reduced when mice treated with PFOS (20 mg/kg/day) for 14 
days, even in normal diet and HFD-group, which related with the reduced secretion and 
impaired function of low density lipoproteins (Wang et al., 2014).
It is interesting to note that PFOS increased insulin-stimulated glucose uptake in 
differentiated adipocytes. A previous study reported that higher serum PFOS concentration 
was positively associated with increased serum insulin levels and insulin resistance (Lin et 
al., 2009), which contrasts with the current study. And Nelson et al. reported that higher 
serum PFOA and PFOS concentration was positively associated with serum cholesterol 
levels, but displayed a weak association with body weight and insulin resistance (Nelson et 
al., 2010). Another in vivo study performed on rats, which the pregnant rats were given with 
PFOS (0.5 or 1.5 mg/kg/day) from gestation day 0 to postnatal day 21. The pups displayed 
impaired glucose tolerance and enhanced insulin resistance index, suggesting PFOS 
disrupted insulin signaling in integrate animal study (Lv et al., 2013). In the current in vitro 
study, we demonstrated that PFOS increased insulin-induced glucose uptake and increased 
gene expression related to insulin signaling. One possible reason is that PFOS increased 
adipogenesis in 3T3-L1 preadipocytes and enhanced adipogenesis increases capacity for 
glucose uptake (Nugent et al., 2001). Also, enhanced Pparγ and Glut4 expression will help 
to promote glucose uptake, as well as improve insulin signaling and insulin-response 
activity. Our previous study reported that enhanced Nrf2 activity by Keap1-KD increased 
glucose tolerance, and increased insulin-stimulated Akt phosphorylation without Glut4 
expression change (Xu et al., 2013), suggesting activation Nrf2 can promote insulin 
signaling, contribute to positively regulate glucose uptake in differentiated 3T3-L1 
preadipocytes.
The study herein reported that PFOS could induce Nrf2 activation in preadipocytes. PFOS 
administration has been shown to increase ROS production, which induces oxidative stress 
and activate Nrf2 signaling (Qian et al., 2010). ARE consensus elements are the typical 
transcriptional factor binding sites, which are described to induce the antioxidant gene 
expression for Nrf2 target genes, such as Ho1, Gclc, Nqo1, and Mrps to provide a protective 
role against oxidative and cytochemical stress (Nguyen et al., 2009). Also, ARE sites have 
been reported in the promoter of Pparγ and Cebpα, which are responsible for 3T3-L1 
preadipocytes adipogenesis (Pi et al., 2010). ARE binding was enhanced after PFOS 
treatment in MEFs isolated from transgenic mice that harbor a ARE sequence coupled to a 
hPAP reporter, suggesting activation of genes via ARE sites is a process that occurs via 
PFOS-induced adipogenesis. Chip assay revealed that PFOS treatment increased Nrf2 
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binding to ARE sites in the mouse Nqo1 promoter in 3T3-L1 cells cultured in induction 
media for 4 days, further confirming that PFOS administration can induce Nrf2 signaling via 
ARE binding during adipogenesis.
Overall, this study reported that novel effects of PFOS in inducing Pparγ and Cebpα 
expression and adipogenesis, via enhancing ARE binding activity and Nrf2 signaling in 
preadipocytes (Figure 7D). Additionally, PFOS increased insulin-stimulated glucose uptake 
and increased gene expression related with insulin signaling. This study points out the 
potential roles of PFOS promoting adipose tissue differentiation and the related metabolic 
conditions of obesity consequentially.
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Highlights
● PFOS induces adipogenesis in association with increased Pparγ and Cebpα 
mRNA expression
● PFOS increases ARE bindingactivity and activates Nrf2 signaling
● PFOS increases insulin-stimulated glucose uptake
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Figure 1. MTT assay of PFOS on 3T3-L1 preadipocytes
The illustration of study design on (A) 3T3-L1 preadipocytes, (B) human visceral 
preadipocytes, and (C) mouse embryonic fibroblasts. (D) 3T3-L1 preadipocytes were 
exposed to PFOS at concentration of 1 nM, 5 nM, 10 nM, 100 nM, 500 nM, 1 µM, 5 µM, 10 
µM, 50 µM, 100 µM or DMSO in DMEM with 10% FBS for 48 hrs. PFOS toxicity at 
different dosage was determined by MTT assay. Data for vehicle-treated group was 
considered as 100%. N=5. *, P<0.05, PFOS-treated vs. vehicle (Veh).
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Figure 2. Non-cytotoxic levels of PFOS enhances lipid content in differentiated 3T3-L1 
preadipocytes
Cells were differentiated 2 days post 100% confluences (Day0) by switching with 
differentiated media containing 10 µg/mL insulin, 1 µM dexamethasone, 0.5 mM 
isobutylmethylxanthine in DMEM with 10% FBS for the first 3 days; then switch to media 
only containing 10 µg/mL insulin in DMEM with 10% FBS for the additional 5 days. 
Indicated concentration of PFOS or vehicle was included in media from Day0 to Day8. (A) 
Representative images of Oil red O staining of 3T3-L1 preadipocytes at indicated 
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concentration of PFOS. (B) Lipids were extracted from differentiated 3T3-L1 adipocytes by 
using chloroform/ methanol mixture, and triglycerides (TG) content was determined 
spectrophotometrically. Relative triglycerides content (%) was displayed using differentiated 
media containing DMSO (0.1%) - treated cells as a standard (Veh). *, P<0.05, PFOS-treated 
vs. vehicle (Veh).
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Figure 3. PFOS increases adipogenic gene expression and induced Nrf2 signaling in 3T3-L1 
preadipocytes
3T3-L1 preadipocytes were induced to differentiation to adipocytes with or without PFOS 
(50 µM) for 3 days. Total RNA was extracted at the indicated time. Relative mRNA levels 
were quantified by quantitative real-time PCR. PFOS increased adipogenic gene expression 
of Cebpα, Pparγ, Fabp4, Lpl (A), and increased Nrf2 signaling of Nrf2, Nqo1, Gclc (B) 
mRNA levels in 3T3-L1 preadipocytes All data were normalized to 18S rRNA levels. *, 
P<0.05, PFOS-treated vs. vehicle (Veh)..
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Figure 4. PFOS promotes insulin-stimulated glucose uptake in 3T3-L1 adipocytes
(A) 3T3-L1 preadipocytes were induced to differentiation to adipocytes for 10 days, then 
treated with PFOS (1, 5, 10, 50, 100 µM) for 5 hrs. Glucose uptake of differentiated 3T3-L1 
preadipocytes was determined by using 2-NBDG according to the manufactory instruction. 
The fluorescence activity was monitored at an excitation wavelength of 485 nm and an 
emission wavelength of 535 nm. Relative glucose uptake was displayed using vehicle-
treated group as a standard. Total RNA was extracted from 3T3-L1 adipocytes after treated 
with PFOS (10 or 50 µM) for 5 hrs. Relative mRNA levels of (B) Pparγ, Srebp1c, Glut4, 
Irs-1, Insr and (C) Nrf2, Nqo1 were quantified by quantitative real-time PCR. All data were 
normalized to 18S rRNA levels. *, P<0.05, PFOS-treated vs. vehicle (Veh).
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Figure 5. Adipogenic gene expression and Nrf2 signaling of Nrf2 and Nqo1 expression increase 
in white adipose tissue from mice administered PFOS
Mice were administrated with PFOS (100 µg/kg/day) for 36 days. Epididymal white adipose 
tissue was collected and total RNA was extracted. (A, B) Relative mRNA levels of the 
indicated gene were quantified by quantitative real-time PCR. All data were normalized to 
18S rRNA levels. *, P<0.05, PFOS-treated vs. vehicle (Veh).
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Figure 6. PFOS increased lipid accumulation in differentiated human visceral preadipocytes
Human visceral preadipocytes obtained from Lonza were induced to differentiation to 
adipocytes by switch with the differentiated media contain dexamethasone, 
isobutylmethylxanthine and insulinSingleQuots™ according to the manufacturer’s 
instructions, with PFOS (5 or 50 µM) or not (0.1% DMSO) for 11 days. (A) Representative 
images of Oil red O staining of differentiated human visceral preadipocytes treated with 
PFOS at indicated concentration. (B) Staining of lipids was extracted from differentiated 
human visceral preadipocytes via isopropanol isolation, and the lipid content was 
determined spectrophotometrically. Relative lipid content (%) was displayed using 
differentiated media containing DMSO (0.1%) -treated cells as a standard (Veh). *, P<0.05, 
PFOS-treated vs. vehicle (Veh).
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Figure 7. FFOS increases hPAP expression and enhances Nrf2 enrichment at ARE sites in mouse 
Nqo1 promoter
(A) Mouse embryonic fibroblasts isolated from ARE-hPAP transgenic mice were induced to 
differentiation to adipocytes for 4 days, then incubated with PFOS (50 µM) for additional 4 
days. Total RNA was extracted and hPAP mRNA levels were quantified by quantitative 
real-time PCR. All data were normalized to 18S rRNA levels. *, P<0.05, PFOS-treated vs. 
vehicle (Veh). (B) 3T3-L1 cells were induced to differentiation for 2 days. Cells were 
collected for Chromatin immunoprecipitation assays using either Nrf2 antibody or IgG as 
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the negative control. A primer targeted for antioxidant response element in mouse Nqo1 
promoter was used for PCR amplification. Non-immunoprecipitated chromation (1%) was 
used as an input control. (C) Relative chip signal for PFOS function on Nrf2 enrichment to 
ARE element of mouse Nqo1 promoter. (D) The work flow for PFOS increased 
adipogenesis via activating Nrf2 signaling and inducing Cebpα, Pparγ expression in 
preadipocytes.
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